Findings

What do systematic reviews say?

3 questions · 4 findings · 2 reviews · Lung Cancer

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 75%High 1 · 25%

Progression‐free survival · People with advanced non‐small cell lung cancer

Gefitinib showed no clear difference in progression‐free survival (PFS) compared with chemotherapy (moderate certainty).

2 findings from 1 review

Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
HR 1.19 [0.86, 1.65]
2 studies · 275 participants
Moderate
Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
HR 1.04 [0.92, 1.17]
2 studies · 1607 participants
Moderate

Progression‐free survival · EGFR M+ patients with NSCLC

Gefitinib leads to lower progression‐free survival compared with paclitaxel + carboplatin (high certainty).

1 finding from 1 review

Progression‐free survival · EGFR M+ patients with NSCLC

Gefitinib probably leads to lower progression‐free survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).

1 finding from 1 review